Home
About
Leadership
Science
Investors
IR Kit
Tear Sheet
Press Releases
Stock Quotes
SEC Filings
Key Contacts
Subscribe to Email Alerts
News
Contact
Stay Ahead
|
|
Search for:
News
November 6, 2020
Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol
September 17, 2020
Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors
June 30, 2020
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
June 2, 2020
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors
April 14, 2020
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD
April 1, 2020
Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
February 18, 2020
Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent
February 11, 2020
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN
January 28, 2020
Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead
January 22, 2020
Kannalife, Inc. Issues Update on Intellectual Property and Patent Estate
January 14, 2020
Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain
January 7, 2020
Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine™
December 18, 2019
CBD: Perils, Promise and Development for Neuropathic Pain
December 11, 2019
Kannalife, Inc. Announces Filing of U.S. Patent 62/934,861 – Functionalized 1, 3 Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders
December 9, 2019
Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol “KLFE”
June 27, 2019
Kannalife, Inc. to Present Breakthrough CIPN Study Findings on the Comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference
May 21, 2019
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
March 24, 2019
Kannalife Spokesman former NFL kicker Nick Lowery on Head Injuries, CBD Treatment
February 5, 2019
Kannalife Spokesman Nick Lowery Wins 2018 CNBC Stock Draft
January 16, 2019
Kannalife Announces Completion of Name Change, Ticker Symbol Change
Home
About
Leadership
Science
Investors
IR Kit
Tear Sheet
Press Releases
Stock Quotes
SEC Filings
Key Contacts
Subscribe to Email Alerts
News
Contact